Jennifer Fulk
Chief Financial OfficerMs. Jennifer Fulk is Chief Financial Officer of Kura Oncology, Inc. from September 8, 2026. Ms. Fulk served as Chief Financial Officer of Soleno Therapeutics, Inc. from March 2, 2026. Ms. Fulk was Chief Financial Officer & Chief Operating Officer of 120 Water Audit, Inc. since 2025. Ms. Fulk was Chief Financial Officer of Talkspace, Inc. from July 26, 2021 to May 2024. She previously served as Chief Financial Officer, U.S. Bio-Medicines at Eli Lilly and Company from June 2019 to July 2021. Prior to June 2019, Ms. Fulk served in various other roles during her career at Eli Lilly and Company, including as Senior Director, Investor Relations, from October 2018 to June 2019, Chief Financial Officer, North America, Elanco, from October 2016 to October 2018 and Senior Director, Global Finance and Integration, Elanco, from September 2014 to October 2016. She has public company experience in leading financial strategy, investor relations, financial reporting and operational efficiency, with a diverse career progression that includes many years at Eli Lilly. Ms. Fulk received her Bachelor of Science in Information Systems and her Masters of Business Administration from Indiana University.
Positions
- Company NameKura Oncology, Inc.Stock CodeKURAPositionChief Financial OfficerColleagues
- TETroy Edward WilsonChairman, CEO & President
- KFKathleen FordChief Operating Officer
- BTBrian T. PowlChief Commercial Officer
- TDThomas DoyleSenior Vice President of Finance & Accounting
- KMKevan M. ShokatChairman of the Scientific Advisory Board
- TRThomas Robert MalleyIndependent Director
- MTMary T. SzelaIndependent Director
- CACarol A. SchaferIndependent Director
